建元信托股份有限公司公告 证券代码：600816 证券简称：建元信托 公告编号：临 2025-027 建元信托股份有限公司 诉讼进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏, 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、前期诉讼案件的进展情况 建元信托股份有限公司（以下简称"公司"、"本公司"、"建元信托"）前 期于《诉讼公告暨前期诉讼进展公告》（公告编号：临 2020-011）中披露了涉及三 峡资本控股有限责任公司（以下简称"三峡资本"）的一宗案件（原案号为（2020） 京 01 民初 23 号），该案件原告为三峡资本，被告为本公司，涉诉金额 49,783.65 万 元。后该案件移送上海金融法院处理（案号为（2020）沪 74 民初 3232 号）。 公司于 2025 年 8 月 27 日收到上海金融法院送达的（2020）沪 74 民初 3232 号 《民事判决书》，判决如下： 1. 被 告 建 元 信 托 应 于 本 判 决 生 效 之 日 起 十 日 内 赔 偿 原 告 三 峡 资 本 155,160,481.17 元； 2. 驳回原 ...

Core Viewpoint - The independent director system is a crucial component of the capital market's foundational structure, aimed at enhancing corporate governance, improving transparency and authenticity of information disclosure, and protecting the interests of minority investors [1] Group 1: Independent Director Activities - During 2024, Guo Yongqing served as an independent director for Shanghai Electric, Jianyuan Trust, and New China Life Insurance, attending all relevant board meetings and shareholder meetings [1] - Shanghai Electric held a total of 13 board meetings and 3 shareholder meetings in 2024, with Guo attending all required meetings and voting in favor of all board resolutions without raising any objections [1] - Jianyuan Trust convened 9 board meetings and 2 shareholder meetings in 2024, with Guo participating in all meetings and similarly voting in favor of all resolutions without dissent [1] - New China Life Insurance conducted 14 board meetings and 3 shareholder meetings in 2024, with Guo attending all meetings and voting in favor of all resolutions without any objections [1] Group 2: Professional Background - Guo Yongqing holds a CPA qualification and obtained a PhD in accounting theory from Shanghai University of Finance and Economics in 2002 [1] - He has previously held positions at Shanghai Haohai Biological Technology Co., Ltd., Sunshine City Group Co., Ltd., and Tianjin Chuangye Environmental Protection Group [1] - Currently, Guo is a professor at Shanghai National Accounting Institute and serves as an independent director for several companies, including Shanghai Electric, Jianyuan Trust, New China Life Insurance, Fosun Tourism Culture Group, and Jiaxing Bank [1]

Group 1 - The core point of the article highlights that Jianyuan Trust has seen a net financing inflow of 26.39 million yuan last week, ranking 458th in the two markets [1] - Jianyuan Trust's financing buy amount last week was 156 million yuan, while the repayment amount was 129 million yuan [1] - The company operates in various sectors including diversified finance, Shanghai sector, S&P, Shanghai Stock Connect, CSI 500, margin trading and securities lending, institutional heavy positions, insurance participation, Yangtze River Delta, and bank participation [1] Group 2 - Over the past 5 days, the main capital outflow from Jianyuan Trust was 11.98 million yuan, with a decline of 0.85% in this period [1] - In the last 10 days, the main capital inflow was 15.69 million yuan, with an increase of 0.61% in this period [1] - Jianyuan Trust, established in 1995 and located in Shanghai, primarily engages in other financial services, with a registered capital of approximately 984.44 million yuan and a paid-in capital of about 640.69 million yuan [1] Group 3 - The legal representative of Jianyuan Trust is Qin Yi [1] - The company has made investments in 60 enterprises and participated in 15 bidding projects [1] - Jianyuan Trust holds 37 trademark registrations and possesses 11 administrative licenses [1]

建元信托股份有限公司公告 因不服上述判决，东证资管提起上诉，请求上海市高级人民法院撤销上海金融 法院作出的（2020）沪 74 民初 2489 号《民事判决书》，改判支持上诉人一审全部 诉讼请求。公司于 2025 年 8 月 19 日收到上海市高级人民法院通知及《传票》，上 海市高级人民法院已受理上诉案件，案号为（2025）沪民终 419 号。 二、相关诉讼事项对公司本期利润或者期后利润等的影响 二审案件尚未开庭，目前暂无法判断相关诉讼对公司本期利润或者期后利润的 影响。公司将依据法律规定程序，积极行使诉讼权利。 公司指定的信息披露媒体为《中国证券报》《证券日报》《上海证券报》和上 证券代码：600816 证券简称：建元信托 公告编号：临 2025-026 建元信托股份有限公司 诉讼进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏, 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、前期诉讼进展情况 公司前期于《诉讼公告暨前期诉讼进展公告》（编号：临 2020-060）、《诉讼 进展公告》（编号：临 2025-014）中披露了涉及上海东方证券资产管理 ...

Core Viewpoint - The lawsuit involving Jianyuan Trust has been accepted by the Shanghai High People's Court, with the case number (2025) Hu Min Zhong 419, and the trial has not yet commenced [1] Group 1: Lawsuit Details - The company is the respondent in the appeal, with Shanghai Dongfang Securities Asset Management Co., Ltd. as the plaintiff [1] - The amount in dispute is 402 million yuan [1] - The Shanghai Financial Court previously dismissed the claims made by Dongfang Asset Management in the first instance, leading to the appeal [1] Group 2: Company Actions - The company will actively exercise its litigation rights in accordance with the law [1] - It is currently not possible to assess the impact of the lawsuit on the company's profits for the current or future periods [1]

Group 1 - The core point of the article highlights the financing activities of Jianyuan Trust, which recorded a financing purchase amount of 0.24 billion yuan on August 19, ranking 962nd in the two markets [1] - Over the last three trading days from August 15 to August 19, Jianyuan Trust received financing purchases of 0.27 billion yuan, 0.29 billion yuan, and 0.24 billion yuan respectively [1] - On the same day, the company experienced a securities lending activity with a sell-off of 20.93 thousand shares, resulting in a net sell-off of 15.37 thousand shares [1]

Core Viewpoint - Qianhong Pharmaceutical has reached a settlement with Jianyuan Trust to recover half of its investment in the "Chuangying 51" trust plan after a five-year dispute, highlighting the ongoing challenges faced by companies in managing trust investments and the impact of external economic conditions on asset performance [2][3][4]. Group 1: Settlement Details - On August 14, Qianhong Pharmaceutical announced it had reached a settlement with Jianyuan Trust regarding the "Chuangying 51" trust plan, resulting in a one-time payment of 56.9943 million yuan, which will be recognized as approximately 48.45 million yuan in profit for the 2025 fiscal year [2][5]. - The total investment in the two trust products purchased in 2018 amounted to 340 million yuan, with both products experiencing overdue payments [3][4]. - The settlement allows Qianhong to retain part of the trust beneficiary rights, indicating a strategy to balance risk while recovering some capital [6]. Group 2: Background of Trust Products - The "Chuangying 51" trust plan was set to mature on December 29, 2019, while the "Ruiying 64" plan was due on August 15, 2019, but both faced overdue payments due to the underlying assets' lack of liquidity and the borrower's financial difficulties [3][4]. - The total amount involved in the lawsuits against Jianyuan Trust was approximately 376.1866 million yuan, with overdue principal totaling 340 million yuan [4]. Group 3: Industry Context - The trend of companies facing challenges with trust investments is not isolated, as evidenced by other firms like Hengyin Technology and Chengdu Road and Bridge, which have also reported significant overdue amounts from trust products [7]. - The current economic environment has led to a preference for lower-risk fixed-income products among listed companies, with 36 companies reportedly investing a total of approximately 8.9 billion yuan in trust products since early 2025, reflecting a shift in investment strategy [7].

Core Viewpoint - Qianhong Pharmaceutical reached a settlement with Jianyuan Trust regarding a payment dispute from a trust plan purchased in 2018, resulting in a one-time payment of 56.9943 million yuan, which will contribute approximately 48.45 million yuan to the company's 2025 profit [1][4]. Group 1: Qianhong Pharmaceutical - Qianhong Pharmaceutical invested 170 million yuan in the "Anxin Chuangyin 51 Hao" trust plan, which was originally due on December 29, 2019 [4]. - After a prolonged legal battle lasting five years, the company agreed to withdraw its lawsuit in exchange for half of the remaining principal and earnings, amounting to 56.9943 million yuan [4]. - The expected profit increase of approximately 48.45 million yuan will be recorded in the 2025 profit statement [4]. Group 2: Jianyuan Trust - Jianyuan Trust reported a total revenue of 150 million yuan for the first half of 2025, marking an 84.89% year-on-year increase, and a net profit of 40 million yuan, up 13.36% [4][5]. - The company added 117 new trust projects in the first half of 2025, corresponding to a new trust scale of 1,080.01 billion yuan, reflecting a 785% year-on-year growth [5]. - As of June 30, 2025, Jianyuan Trust's managed trust assets reached 3,378.91 billion yuan, a 33.44% increase from the beginning of the year [5]. Group 3: Financial Performance and Business Development - In 2024, Jianyuan Trust achieved total revenue of 310 million yuan, with a net profit of 53 million yuan, representing a 25.15% year-on-year growth [7]. - The company’s solid business became a significant pillar, with interest income from proprietary business increasing by 12% to 32.5149 million yuan [7]. - Jianyuan Trust's trust asset management scale reached 2,532 billion yuan by the end of 2024, with a substantial growth of 78% from the beginning of the year [7].

Core Viewpoint - The announcement details the litigation progress of Jianyuan Trust Co., Ltd., including settlements and arbitration outcomes, which may impact the company's financials. Group 1: Litigation Status - One case has been settled and withdrawn, one arbitration ruling has been revoked, and one case has been withdrawn [2] - The company is a defendant in the settled and withdrawn cases, while it is the applicant in the revoked arbitration case [2] Group 2: Financial Implications - The settled case involved a litigation amount of 177.87 million yuan, the revoked arbitration case involved a principal amount of 10 million yuan, and the withdrawn case involved 365,600 yuan [2] - The company will recognize liabilities based on the settlement results for the settled case, and will reverse previously recognized liabilities for the revoked arbitration case [2][7] Group 3: Specific Case Details - In the case involving Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., a settlement agreement was signed on August 13, 2025, with the company paying 56.99 million yuan [3][4] - The company received a civil ruling allowing the withdrawal of the case, with the litigation costs borne by Changzhou Qianhong [4] Group 4: Other Litigation Developments - In the case involving Haoke Technology Co., Ltd., the company was ordered to return a trust principal of 10 million yuan, but the arbitration ruling was later revoked by the Shanghai Financial Court [5][6] - A separate case involving a natural person had its claim amount adjusted from 1.6 million yuan to 365,600 yuan [7]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Jianyuan Trust, which has a high rolling PE ratio of 506.58 times, significantly above the industry average of 48.52 times [1][2] - As of June 30, 2025, Jianyuan Trust has 86,323 shareholders, an increase of 12,051 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - For the first half of 2025, Jianyuan Trust reported a revenue of 150 million yuan, representing a year-on-year increase of 84.89%, and a net profit of approximately 40.29 million yuan, reflecting a year-on-year growth of 13.36% [1] Group 2 - Jianyuan Trust's main business includes proprietary and trust services, with its primary products being in these areas [1] - The company ranks 21st in terms of PE ratio within the diversified financial industry, which has a median PE of 29.68 times [1][2] - The total market capitalization of Jianyuan Trust is approximately 29.336 billion yuan [1][2]